Fenfluramine Treatment Is Associated With Improvement in Everyday Executive Function in Adults With Lennox-Gastaut Syndrome: Post-Hoc Analysis of Dose Effects From a Phase 3 Trial Rationale

Author:Bishop, Kim   Isquith, Peter   Knupp, Kelly   Sullivan, Joseph   Nabbout, Rima   Gil-Nagel, Antonio   Scheffer, Ingrid   Auvin, Stéphane   Cross, J Helen   Guerrini, Renzo   Roth, Robert   Gioia, Gerard   Lothe, Amélie   Polega, Shikha   

Session Name:P11: Epilepsy/Clinical Neurophysiology (EEG): ASMs Clinical Trial 1  

Topic:Epilepsy/Clinical Neurophysiology (EEG)  

Program Number:P11.001  

Author Institution:Global Pharma Consultancy, LLC, Muncy, PA  Global Pharma Consultancy, LLC  Boston Children’s Hospital, Harvard Medical School, Boston, MA  Children's Hospital Colorado, Aurora, CO  University of California San Francisco, Benioff Children’s Hospital, San Francisco, CA  Reference Centre for Rare Epilepsies, Hôpital Universitaire Necker-Enfants Malades, APHP, Member of EPICARE, Institut Imagine, Université Paris Cité, Paris, France  Hospital Ruber Internacional, Madrid, Spain  University of Melbourne, Austin Hospital and Royal Children’s Hospital, Florey Institute and Murdoch Children’s Research Institute, Heidelberg, Australia  Robert Debré University Hospital, APHP, Université de Paris, Institut Universitaire de France (IUF), Paris, France  UCL NIHR BRC Great Ormond Street Institute of Child Health, London, United Kingdom  Anna Meyer Children's Hospital, University of Florence, Milan, Italy  Dartmouth-Hitchcock Medical Center, Lebanon, NH  Children’s National Health System, Rockville, MD  Zogenix International (now a part of UCB), Maidenhead, United Kingdom  Zogenix, Inc. (now a part of UCB), Emeryville, CA